Flavopiridol (L86-8275)

For research use only. Not for use in humans.

目录号：S1230 别名： NSC 649890 HCl, HMR-1275, Alvocidib 中文名称：夫拉平度

Flavopiridol (L86-8275) Chemical Structure

CAS No. 146426-40-6

Flavopiridol (L86-8275, Alvocidib, NSC 649890, HMR-1275) 与ATP竞争性抑制CDKs，包括CDK1、CDK2、CDK4、CDK6和CDK9的IC50范围为20-100 nM。作用于CDK1、2、4、6、9比作用于CDK7更具有选择性。Flavopiridol最初被发现能抑制EGFR和PKA。Flavopiridol可诱导自噬和内质网应激反应。Flavopiridol可阻滞HIV-1的复制。Phase 1/2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 810.81	现货
5mg	RMB 647.01	现货
25mg	RMB 1386.75	现货
100mg	RMB 4668.25	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Flavopiridol (L86-8275)发表文献81篇：

Nature, 2021, 10.1038/s41586-021-03445-y

PubMed: 33854235 ( click the link to review the publication )

Nature, 2020, 580(7801):147-150

PubMed: 32238924 ( click the link to review the publication )

Nat Med, 2019, 25(2):292-300

PubMed: 30664779 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Genome Res, 2021, 31(6):981-994

PubMed: 34006569 ( click the link to review the publication )

J Cell Biol, 2021, 220(7)e202008146

PubMed: 33881484 ( click the link to review the publication )

J Control Release, 2021, 333:246-257

PubMed: 33798663 ( click the link to review the publication )

PLoS Pathog, 2021, 17(4):e1009567

PubMed: 33909709 ( click the link to review the publication )

Biomolecules, 2021, 11(6)781

PubMed: 34067359 ( click the link to review the publication )

Nat Commun, 2021, 12(1):808

PubMed: 33547292 ( click the link to review the publication )

Pharmaceuticals (Basel), 2021, 14(7)598

PubMed: 34206464 ( click the link to review the publication )

Mol Cell, 2020, 7;S1097-2765(20)30269-0

PubMed: 32416067 ( click the link to review the publication )

J Clin Invest, 2020, 134132

PubMed: 33016930 ( click the link to review the publication )

Nucleic Acids Res, 2020, 24;gkaa268

PubMed: 32329774 ( click the link to review the publication )

EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

Dev Cell, 2020, 55(6):707-722.e9

PubMed: 33321102 ( click the link to review the publication )

Cell Rep, 2020, 7;31(1):107485

PubMed: 32268092 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 26;5:17

PubMed: 32140264 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 26;5(1):17

PubMed: 32296028 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):984

PubMed: 33046037 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2020, 14:167-182

PubMed: 33125935 ( click the link to review the publication )

PLoS One, 2020, 15(9):e0239315

PubMed: 32970704 ( click the link to review the publication )

Viruses, 2020, 12(10)E1067

PubMed: 32977702 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )
Cell Signal, 2020, 67:109508

PubMed: 31866490 ( click the link to review the publication )

Cell Res, 2019, 29(9):725-738

PubMed: 31273297 ( click the link to review the publication )

Mol Cell, 2019, 73(4):670-683.e12

PubMed: 30639241 ( click the link to review the publication )

Mol Cell, 2019, 74(4):651-663.e8

PubMed: 30954402 ( click the link to review the publication )

EMBO J, 2019, 38(19):e101704

PubMed: 31429971 ( click the link to review the publication )

Dev Cell, 2019, 49(3):425-443

PubMed: 31063758 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(26):12986-12995

PubMed: 31182587 ( click the link to review the publication )

Cancer Res, 2019, 79(19):5088-5101

PubMed: 31416846 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2208-2219

PubMed: 30885981 ( click the link to review the publication )

PLoS Pathog, 2019, 15(3):e1007667

PubMed: 30901352 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(1):121-130

PubMed: 30472117 ( click the link to review the publication )

Lab Invest, 2019, 99(5):612-624

PubMed: 30664711 ( click the link to review the publication )

Sci Rep, 2019, 9(1):17369

PubMed: 31758083 ( click the link to review the publication )

Sci Adv, 2019, 5(6):eaaw3593

PubMed: 31183407 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(8):3921-3936

PubMed: 30805632 ( click the link to review the publication )

J Cell Sci, 2019, 132(18)jcs233379

PubMed: 31427428 ( click the link to review the publication )

J Exp Med, 2018, 215(12):3194-3212

PubMed: 30463877 ( click the link to review the publication )

J Exp Med, 2018, 215(12):3115-3135

PubMed: 30487290 ( click the link to review the publication )

Elife, 2018, 7e40228

PubMed: 30465651 ( click the link to review the publication )

Oncogene, 2018, 37(28):3763-3777

PubMed: 29636547 ( click the link to review the publication )

Sci Signal, 2018, 11(530)

PubMed: 29764992 ( click the link to review the publication )

Br J Cancer, 2018,

PubMed: 29241222 ( click the link to review the publication )

Cell Oncol (Dordr), 2018, 41(6):663-675

PubMed: 30178167 ( click the link to review the publication )

Oncotarget, 2018, 9(100):37352-37366

PubMed: 30647837 ( click the link to review the publication )
Oncotarget, 2018, 9(34):23505-23518

PubMed: 29805751 ( click the link to review the publication )

Oncotarget, 2018, 9(5): 6174–6187

PubMed: 29464063 ( click the link to review the publication )

Oncotarget, 2018, 9(9):8560-8572

PubMed: 29492217 ( click the link to review the publication )

EMBO J, 2017, 36(2):202-212

PubMed: 27852626 ( click the link to review the publication )

Cell Biosci, 2017, 7:43

PubMed: 28852468 ( click the link to review the publication )

PLoS One, 2017, 12(5):e0177871

PubMed: 28520795 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:439-446

PubMed: 28176922 ( click the link to review the publication )

Oncotarget, 2017, 8(68):112313-112329

PubMed: 29348827 ( click the link to review the publication )

Oncotarget, 2017, 8(35):59476-59491

PubMed: 28938651 ( click the link to review the publication )

Cancer Res, 2016, 76(5):1158-69

PubMed: 26627013 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(10):2555-64

PubMed: 26603262 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(10):3203-3219

PubMed: 27486199 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(2):366-81

PubMed: 26922519 ( click the link to review the publication )

Trop Life Sci Res, 2016, 27(supp1):125-130

PubMed: 27965750 ( click the link to review the publication )

Nat Commun, 2015, 6:8481

PubMed: 26412466 ( click the link to review the publication )

Leukemia, 2015, 10.1038/leu.2015.99

PubMed: 25882699 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(4):2062-71

PubMed: 25624324 ( click the link to review the publication )

Sci Rep, 2015, 5:10120

PubMed: 25944566 ( click the link to review the publication )

Front Neural Circuits, 2015, 9:63

PubMed: 26539083 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2015, 76(1):105-16

PubMed: 25986678 ( click the link to review the publication )

Leukemia, 2014, 28(3):629-41

PubMed: 24263804 ( click the link to review the publication )

Water Res, 2014, 61:67-76

PubMed: 24880958 ( click the link to review the publication )

ACS Chem Biol, 2014, 10.1021/cb500072z

PubMed: 24568369 ( click the link to review the publication )

Front Cell Neurosci, 2014, 8:39

PubMed: 24596543 ( click the link to review the publication )
PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )

Nucl Med Biol, 2014, 41(10):856-62

PubMed: 25195014 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Int J Cancer, 2013, 133(10):2341-50

PubMed: 23640782 ( click the link to review the publication )

Cell Cycle, 2013, 12(23):3689-701

PubMed: 24189531 ( click the link to review the publication )

PLoS One, 2013, 8(12):e83467

PubMed: 24376706 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(11):2321-30

PubMed: 22964485 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(20):8414-9

PubMed: 21536883 ( click the link to review the publication )

Mol Cancer Ther, 2011, 10(9):1624-34

PubMed: 21768328 ( click the link to review the publication )

产品安全说明书

CDK抑制剂选择性比较

生物活性

产品描述

特性

Flavopiridol是第一个应用于人临床实验的细胞周期蛋白依赖性激酶抑制剂。

靶点

CDK9 ^[8] (Cell-free assay)	CDK1 ^[8] (Cell-free assay)	CDK4 ^[9] (Cell-free assay)	CDK2 ^[8] (Cell-free assay)	CDK6 ^[9] (Cell-free assay)	点击更多
20 nM	30 nM	20-40 nM	40 nM	60 nM	点击更多

体外研究

作为CDK广谱抑制剂，Flavopiridol可以抑制细胞周期进展，使其停在G1期或G2期。0.3 μM Flavopiridol作用于MCF-7或MDA-MB-468细胞，通过抑制CDK4或CDK2激酶活性，而诱导细胞周期停在G1 期。^[4] Flavopiridol 作用于无关激酶，如MAP, PAK, PKC, 和 EGFR，活性低很多，IC50 >14 μM。Flavopiridol 显著抑制HCT116, A2780, PC3, 和 Mia PaCa-2 细胞集落生长，IC50分别为 13 nM, 15 nM, 10 nM, 和 36 nM。^[1] Flavopiridol作用于多种肿瘤细胞系，具有细胞毒性，IC50为作用于LNCAP 的 16 nM 到作用于 K562的130 nM。^[5] Flavopiridol也有效抑制糖原合成激酶-3(GSK-3) 的活性，IC50为 280 nm。^[2]与其他CDKs相比, Flavopiridol抑制CDK7活性时效果稍弱，IC50为875 nM。 Flavopiridol (0.5 μM) 抑制pSer807/811 Rb 和pThr199 NPM,而在pThr821 Rb上观察到轻微变化。Flavopiridol也降低全部RNA聚合酶 II 水平, 及 RNA聚合酶 II在 CTD重复序列在 Ser2 Ser5位点磷酸化。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
MCF-7 tumor cell	M{L3Z3Bzd2yrZnXyZZRqd25iYYPzZZk>			MWXJcohq[mm2aX;uJI9nKE2FRj23JJR2dW:{IHPlcIwheHKxbHnm[ZJifGmxbh?=	MkHQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB6NEOyNVEoRjFyOESzNlEyRC:jPh?=
PC3 cell	M{TIU2Z2dmO2aX;uJIF{e2G7			M2fn[GlvcGmkaYTpc44hd2ZiUFOzJINmdGxiY3zvco9o\W6rYzDhd5NigSxiSVO1NF0yOCEQvF2=	NXG5b5dnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGwOlM3ODlpPkGxNFY{PjB7PD;hQi=>
HCT116 cell	MkK4SpVv[3Srb36gZZN{[Xl?			MlrKTY5pcWKrdHnvckBw\iCKQ2SxNVYh[2WubDDjcI9vd2enbnnjJIF{e2G7LDDJR\|UxRTF\|IN88US=>	M{PBPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzME[zOlA6Lz5zMUC2N\|YxQTxxYU6=
A2780 cell	M2qxOmZ2dmO2aX;uJIF{e2G7			MorHTY5pcWKrdHnvckBw\iCDMke4NEBk\WyuIHPsc45w\2WwaXOgZZN{[XoxvJygTWM2OD1zNTFOwG0>	NWXyfpV6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGwOlM3ODlpPkGxNFY{PjB7PD;hQi=>
Mia PaCa-2 cell	NG\yZY1HfW6ldHnvckBie3OjeR?=			MmXyTY5pcWKrdHnvckBw\iCPaXGgVIFE[S1{IHPlcIwh[2yxbn;n[Y5q[yCjc4PhfUwhUUN3ME2zOkDPxE1?	M{\4b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzME[zOlA6Lz5zMUC2N\|YxQTxxYU6=
LNCaP human prostate carcinoma cell	M{nKWnBzd2yrZnXyZZRqd25iYYPzZZk>			NVjxVJZpUW6qaXLpeIlwdiCxZjDMUmNiWCCqdX3hckBxem:\|dHH0[UBk[XKlaX7vcYEh[2WubDDwdo9tcW[ncnH0bY9v	Mmr1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN\|E{RC:jPh?=
HCT116/VP35 human colon carcinoma cell	NHLKXpVRem:uaX\ldoF1cW:wIHHzd4F6			NITvNm5KdmirYnn0bY9vKG:oIFjDWFEyPi:YUEO1JIh2dWGwIHPvcI9vKGOjcnPpco9u[SClZXzsJJBzd2yrZnXyZZRqd25uIFnDOVA:OTdibl2=	NXzicmlSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKxPVA{OTNpPkGyNVkxOzF\|PD;hQi=>
HCT116 human colon carcinoma cell	M2nORXBzd2yrZnXyZZRqd25iYYPzZZk>			M3fWT2lvcGmkaYTpc44hd2ZiSFPUNVE3KGi3bXHuJINwdG:wIHPhdoNqdm:vYTDj[YxtKHC{b3zp[oVz[XSrb36sJGlEPTB;MUigcm0>	NIO1bGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
HCT116/VM46 human colon carcinoma cell	M3XkRnBzd2yrZnXyZZRqd25iYYPzZZk>			M4LXemlvcGmkaYTpc44hd2ZiSFPUNVE3N1[PNE[gbJVu[W5iY3;sc44h[2G{Y3nuc41iKGOnbHygdJJwdGmoZYLheIlwdixiSVO1NF0zOSCwTR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
A2780/DDP-R human ovarian carcinoma cell	M2rmfXBzd2yrZnXyZZRqd25iYYPzZZk>			M3[3cmlvcGmkaYTpc44hd2ZiQUK3PFAwTESSLWKgbJVu[W5ib4\hdolidiClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR\|UxRTN6IH7N	NETTZ2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
ABAE human fibroblast cell	NE\Ic5RRem:uaX\ldoF1cW:wIHHzd4F6			NH;HUWJKdmirYnn0bY9vKG:oIFHCRWUhcHWvYX6g[oljem:kbHHzeEBk\WyuIIDyc4xq\mW{YYTpc44tKEmFNUC9OFUhdk1?	NWnneHk2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKxPVA{OTNpPkGyNVkxOzF\|PD;hQi=>
HL60 human leukemia cell	Mom0VJJwdGmoZYLheIlwdiCjc4PhfS=>			NGf3cndKdmirYnn0bY9vKG:oIFjMOlAhcHWvYX6gcIV2c2WvaXGgZ4VtdCCycn;sbYZmemG2aX;uMEBKSzVyPUS2JI5O	NUWzTG9mRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKxPVA{OTNpPkGyNVkxOzF\|PD;hQi=>
Hs 27 human fibroblast cell	NFzkbXpRem:uaX\ldoF1cW:wIHHzd4F6			NYTqVWU{UW6qaXLpeIlwdiCxZjDId{AzPyCqdX3hckBncWK{b3LsZZN1KGOnbHygdJJwdGmoZYLheIlwdixiSVO1NF02OSCwTR?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
CCRF-CEM human leukemia cell	MnvOVJJwdGmoZYLheIlwdiCjc4PhfS=>			NHLSSY9KdmirYnn0bY9vKG:oIFPDVmYuS0WPIHj1cYFvKGyndXvlcYliKGOnbHygdJJwdGmoZYLheIlwdixiSVO1NF02OiCwTR?=	M1fOVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN\|E{Lz5zMkG5NFMyOzxxYU6=
OVCAR-3 human ovarian carcinoma cell	MXPQdo9tcW[ncnH0bY9vKGG\|c3H5			MmnwTY5pcWKrdHnvckBw\iCRVlPBVk0{KGi3bXHuJI93[XKrYX6gZ4Fz[2mwb33hJINmdGxicILvcIln\XKjdHnvckwhUUN3ME21OEBvVQ>?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
A2780/DDP-S human ovarian carcinoma cell	NUTQc5N{WHKxbHnm[ZJifGmxbjDhd5NigQ>?			NYn0[GZPUW6qaXLpeIlwdiCxZjDBNlc5OC:GRGCtV{BpfW2jbjDveoFzcWGwIHPhdoNqdm:vYTDj[YxtKHC{b3zp[oVz[XSrb36sJGlEPTB;NU[gcm0>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
A2780/TAX-S human ovarian carcinoma cell	Mn:2VJJwdGmoZYLheIlwdiCjc4PhfS=>			NVOzVld3UW6qaXLpeIlwdiCxZjDBNlc5OC:WQWitV{BpfW2jbjDveoFzcWGwIHPhdoNqdm:vYTDj[YxtKHC{b3zp[oVz[XSrb36sJGlEPTB;NkWgcm0>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
LS174T human colon carcinoma cell	MonUVJJwdGmoZYLheIlwdiCjc4PhfS=>			NXjpb2JjUW6qaXLpeIlwdiCxZjDMV\|E4PFRiaIXtZY4h[2:ub36gZ4Fz[2mwb33hJINmdGxicILvcIln\XKjdHnvckwhUUN3ME22OUBvVQ>?	M1XkPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN\|E{Lz5zMkG5NFMyOzxxYU6=
MCF-7 human breast carcinoma cell	NUf1UHh[WHKxbHnm[ZJifGmxbjDhd5NigQ>?			MlnQTY5pcWKrdHnvckBw\iCPQ1[tO{BpfW2jbjDidoVie3RiY3HyZ4lvd22jIHPlcIwheHKxbHnm[ZJifGmxbjygTWM2OD14NjDuUS=>	NXvCRW9lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKxPVA{OTNpPkGyNVkxOzF\|PD;hQi=>
PC3 human prostate carcinoma cell	MmPhVJJwdGmoZYLheIlwdiCjc4PhfS=>			NG\VS45KdmirYnn0bY9vKG:oIGDDN{BpfW2jbjDwdo9{fGG2ZTDjZZJkcW6xbXGgZ4VtdCCycn;sbYZmemG2aX;uMEBKSzVyPU[2JI5O	MmHwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN\|E{RC:jPh?=
MLF mouse lung fibroblast cell	MULQdo9tcW[ncnH0bY9vKGG\|c3H5			MlXGTY5pcWKrdHnvckBw\iCPTF[gcY92e2VibIXu[{BncWK{b3LsZZN1KGOnbHygdJJwdGmoZYLheIlwdixiSVO1NF04OiCwTR?=	MoL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN\|E{RC:jPh?=
LX-1 human lung carcinoma	MVrQdo9tcW[ncnH0bY9vKGG\|c3H5			NXWxUnN7UW6qaXLpeIlwdiCxZjDMXE0yKGi3bXHuJIx2dmdiY3HyZ4lvd22jIIDyc4xq\mW{YYTpc44tKEmFNUC9O\|Uhdk1?	MnLFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN\|E{RC:jPh?=
A431 human squamous cell	MlvDVJJwdGmoZYLheIlwdiCjc4PhfS=>			M{W2eWlvcGmkaYTpc44hd2ZiQUSzNUBpfW2jbjDzdZVidW:3czDj[YxtKGOjcnPpco9u[SClZXzsJJBzd2yrZnXyZZRqd25uIFnDOVA:PzVibl2=	NX2zc2h2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKxPVA{OTNpPkGyNVkxOzF\|PD;hQi=>
SKBR-3 human breast carcinoma cell	MYXQdo9tcW[ncnH0bY9vKGG\|c3H5			M3Ls[mlvcGmkaYTpc44hd2ZiU1vCVk0{KGi3bXHuJIJz\WG\|dDDjZZJkcW6xbXGgZ4VtdCCycn;sbYZmemG2aX;uMEBKSzVyPUe3JI5O	M1jx[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN\|E{Lz5zMkG5NFMyOzxxYU6=
A2780/TAX-R human ovarian carcinoma cell	MnfJVJJwdGmoZYLheIlwdiCjc4PhfS=>			MmjwTY5pcWKrdHnvckBw\iCDMke4NE9VSVhvUjDoeY1idiCxdnHybYFvKGOjcnPpco9u[SClZXzsJJBzd2yrZnXyZZRqd25uIFnDOVA:Pzhibl2=	MnzQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN\|E{RC:jPh?=
M109 mouse lung carcinoma cell	MVrQdo9tcW[ncnH0bY9vKGG\|c3H5			MWrJcohq[mm2aX;uJI9nKE1zMEmgcY92e2VibIXu[{Bk[XKlaX7vcYEh[2WubDDwdo9tcW[ncnH0bY9vNCCLQ{WwQVgxKG6P	MlPXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN\|E{RC:jPh?=
CACO-2 human colon carcinoma cell	NYPNW5FvWHKxbHnm[ZJifGmxbjDhd5NigQ>?			M2rQ[mlvcGmkaYTpc44hd2ZiQ1HDU{0zKGi3bXHuJINwdG:wIHPhdoNqdm:vYTDj[YxtKHC{b3zp[oVz[XSrb36sJGlEPTB;OE[gcm0>	NXvZXpZbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKxPVA{OTNpPkGyNVkxOzF\|PD;hQi=>
A549 human lung carcinoma cell	M4[wS3Bzd2yrZnXyZZRqd25iYYPzZZk>			M4qyVGlvcGmkaYTpc44hd2ZiQUW0PUBpfW2jbjDseY5oKGOjcnPpco9u[SClZXzsJJBzd2yrZnXyZZRqd25uIFnDOVA:QTZibl2=	NI\UPJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
MIP human colon carcinoma cell	MV\GeY5kfGmxbjDhd5NigQ>?			NYK2WHVGUW6qaXLpeIlwdiCxZjDNTXAhcHWvYX6gZ49td25iY3HyZ4lvd22jIHPlcIwhdGmwZTygTWM2OD1yLkGyJO69VQ>?	Mk\wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN\|E{RC:jPh?=
K562 human leukemia cell	NILCSotRem:uaX\ldoF1cW:wIHHzd4F6			MmHlTY5pcWKrdHnvckBw\iCNNU[yJIh2dWGwIHzleYtmdWmjIHPlcIwheHKxbHnm[ZJifGmxbjygTWM2OD1yLkGzJO69VQ>?	Mo\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN\|E{RC:jPh?=
human A2780 cell line	M2Tjd3Bzd2yrZnXyZZRqd25iYYPzZZk>		M1P1VVczKGh?	M{nFVWFvfGmycn;sbYZmemG2aY\lJIVn\mWldDDh[4FqdnO2IHj1cYFvKEF{N{iwJINmdGxibHnu[UB4[XNiZHX0[ZJucW6nZDDpckBiKHeqb3zlJINmdGxiN{KgbJIh[3m2b4TvfIlkcXS7IHHzd4F6NCCLQ{WwQVcyKG6P	NYjtfpZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUWwNlc5PjNpPkG1NFI4QDZ\|PD;hQi=>
human ovarian (A2780) cancer cell	MlX0R5l1d3SxeHnjxsBie3OjeR?=			M2S1emN6fG:2b4jpZ{Bm\m[nY4Sgc44hcHWvYX6gc5ZiemmjbjCoRVI4QDBrIHPhcoNmeiClZXzsJIxqdmVuIFnDOVA:PzFibl2=	MmTMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTVzMkW5O\|EoRjF3MUK1PVcyRC:jPh?=
ID8 cells	M37k[XBzd2yrZnXyZZRqd25iYYPzZZk>			M{LTb2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgTWQ5KGOnbHzzMEBKSzVyPUegcm0>	NGmxR289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{GyN\|gzOSd-MUexNlM5OjF:L3G+
MCF7 cells	MU\Qdo9tcW[ncnH0bY9vKGG\|c3H5			MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IF3DSlch[2WubIOsJGlEPTB;Mk[gcm0>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF{M{iyNUc,OTdzMkO4NlE9N2F-
Sf9 cells	MoraSpVv[3Srb36gZZN{[Xl?			MXnJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHP5Z4xqdiCDL1PET\|Ih\XiycnXzd4VlKGmwIGPmPUBk\WyuczygTWM2OD1zMjDuUS=>	NGHSW4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{mwOFM3Pid-MUe5NFQ{PjZ:L3G+
human A2780 cells	NFL5O\|FHfW6ldHnvckBie3OjeR?=			M2LKNWlvcGmkaYTpc44hd2ZiY3TrMY1m\GmjdHXkJG5RVSCyaH;zdIhwenmuYYTpc44h[XRidHjyNVk6KGmwIHj1cYFvKEF{N{iwJINmdGy\|	NF7jO\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOES2PVgxQSd-MUi0Olk5ODl:L3G+
human A2780 cells	M333d2Z2dmO2aX;uJIF{e2G7		NVXYN4lmOjRiaB?=	NFviXG1KdmirYnn0bY9vKG:oIHPkb{1u\WSrYYTl[EBT[iCyaH;zdIhwenmuYYTpc44h[XRidHjyPFIyKGmwIHj1cYFvKEF{N{iwJINmdGy\|IHHmeIVzKDJ2IHjydy=>	M1TSUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NE[5PFA6Lz5zOES2PVgxQTxxYU6=
human NCI60 cells	MV\Qdo9tcW[ncnH0bY9vKGG\|c3H5		M3XWTlczKGh?	MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FSU[wJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGG\|c3H5MEBIUTVyPUe0Mlchdk1?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB6MEewN{c,OjFyOEC3NFM9N2F-
human NCI60 cells	NEG4Z5VRem:uaX\ldoF1cW:wIHHzd4F6		M{\tNVczKGh?	NVr2eFdsSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2k3OCClZXzsd{Bie3Onc4Pl[EBieyCuZYToZYwh\W[oZXP0JIFnfGW{IEeyJIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCOQ{WwQVAvQTB2IN88US=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB6MEewN{c,OjFyOEC3NFM9N2F-
human A2780 cells	Mkn2R5l1d3SxeHnjxsBie3OjeR?=		NH:wfXMzPCCq	M4CwWGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGEzPzhyIHPlcIx{KGGodHXyJFI1KGi{czDifUBOXFRiYYPzZZktKEeLNUC9NlMhdk1?	NXnOUmZHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFE4PjdpPkKzN\|AyPzZ5PD;hQi=>
human MRC5 cells	MlzQR5l1d3SxeHnjxsBie3OjeR?=		NF;LenQ4OiCq	MofJR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXJEPSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBIUTVyPUK4JI5O	NFnSTYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwNVc3Pyd-MkOzNFE4Pjd:L3G+
human A2780 cells	MXLDfZRwfG:6aXRCpIF{e2G7		M3flXFczKGh?	MnXCR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhT0l3ME2yPUBvVQ>?	NXjwbnN5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFE4PjdpPkKzN\|AyPzZ5PD;hQi=>
human A2780 cells	MWLDfZRwfG:6aXRCpIF{e2G7		NITwdFM1QCCq	NHPoVYlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOjd6MDDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCJSUWwQVMyKG6P	MkX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEG3OlcoRjJ\|M{CxO\|Y4RC:jPh?=
human MRC5 cells	M1HSe2N6fG:2b4jpZ:Kh[XO\|YYm=		NVTUdnVSPDhiaB?=	NE\yUYtEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOWkN3IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEeLNUC9N\|khdk1?	MkW5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEG3OlcoRjJ\|M{CxO\|Y4RC:jPh?=
human MRC5 cells	MVvDfZRwfG:6aXRCpIF{e2G7		M4DJbFI1KGh?	MoLBR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXJEPSClZXzsd{Bi\nSncjCyOEBpenNiYomgUXRVKGG\|c3H5MEBIUTVyPUS5JI5O	NGCwS5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwNVc3Pyd-MkOzNFE4Pjd:L3G+
human HMEC1 cells	M3rCfmN6fG:2b4jpZ:Kh[XO\|YYm=		MlztNlQhcA>?	NYTCeI9YS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUE2HQ{GgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KE2WVDDhd5NigSxiR1m1NF03OSCwTR?=	MlXMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEG3OlcoRjJ\|M{CxO\|Y4RC:jPh?=
human HMEC1 cells	NUn4V\|I6S3m2b4TvfIlkyqCjc4PhfS=>		MUK0PEBp	NIjvR5JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVUWFMTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCJSUWwQVYzKG6P	M1nrd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CxO\|Y4Lz5{M{OwNVc3PzxxYU6=
human HMEC1 cells	MUnDfZRwfG:6aXRCpIF{e2G7		NF3wc\|c4OiCq	MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUWVEOSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBIUTVyPU[2JI5O	NXrpUVdvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFE4PjdpPkKzN\|AyPzZ5PD;hQi=>
A2780	MoriSpVv[3Srb36gZZN{[Xl?	M2j5e\|M{OCCwTR?=	Mn\yNlQhcHJ?	NH3kV2lR\XKlZX70ZYdmKEF{N{iwJINmdGy\|IHnuJJNjNUdzIHHmeIVzKDJ2IHjyJJIh[XRiM{OwJI5OKCiLQ{WwLUwhS2WubDDjfYNt\SB;IECuNFAyKM7:TT6=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
A2780	M{jGRmFxd3C2b4Ppd{Bie3OjeR?=	NX[0WFh3OzNyIH7N	MWiyOEBpeg>?	NEDvUHpCeG:ydH;0bYMhSTJ5OECgZ4VtdHNiYX\0[ZIhOjRiaIKgdkBifCB\|M{Cgcm0hMEmFNUCpMEBE\WyuIHP5Z4xmKD1iMD6wNFEh\|ryPLh?=	NHjlRXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
A2780	MkDoSpVv[3Srb36gZZN{[Xl?	MYOyPVgxKG6P	MV[yOEBpeg>?	MkjIVIVz[2WwdHHn[UBCOjd6MDDj[YxteyCrbjDzeYIuTzFiYX\0[ZIhOjRiaIKgdkBifCB{OUiwJI5OKCiLQ{mwLUwhS2WubDDjfYNt\SB;IECuNFAzKM7:TT6=	MnX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN\|E{RC:jPh?=
A2780	MWjBdI9xfG:\|aYOgZZN{[Xl?	NFPT[pUzQThyIH7N	NFfBU28zPCCqch?=	MoDGRZBweHSxdHnjJGEzPzhyIHPlcIx{KGGodHXyJFI1KGi{IIKgZZQhOjl6MDDuUUApUUN7MDmsJGNmdGxiY4njcIUhRSByLkCwPUDPxE1w	NHTw[W09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
A2780	MkfySpVv[3Srb36gZZN{[Xl?	NX\ER5AzOjl6MDDuUS=>	NXj6eoJVOjRiaIK=	MYjQ[ZJk\W62YXflJGEzPzhyIHPlcIx{KGmwIGOtdIhie2ViYX\0[ZIhOjRiaIKgdkBifCB{OUiwJI5OKCiLQ{mwLUwhS2WubDDjfYNt\SB;IECuNFEzKM7:TT6=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
A2780	MkPnSpVv[3Srb36gZZN{[Xl?	MVuzN\|Ahdk1?	NHjHU4QzPCCqch?=	M13D[3BmemOnboTh[4UhSTJ5OECgZ4VtdHNiaX6gV{1xcGG\|ZTDh[pRmeiB{NDDodkBzKGG2IEOzNEBvVSBqSVO1NEktKEOnbHygZ5lkdGViPTCwMlAyPiEQvF2u	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
A2780	MknWSpVv[3Srb36gZZN{[Xl?	NXrjS\|ZLOzNyIH7N	MXOyOEBpeg>?	MYHQ[ZJk\W62YXflJGEzPzhyIHPlcIx{KGmwIFeyM20h[W[2ZYKgNlQhcHJicjDheEA{OzBibl2gLGlEPTBrLDDD[YxtKGO7Y3zlJF0hOC5yMkOg{txONg>?	MljUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN\|E{RC:jPh?=
A2780	M{eyUGZ2dmO2aX;uJIF{e2G7	NInFRWIzQThyIH7N	MWGyOEBpeg>?	M2nSOXBmemOnboTh[4UhSTJ5OECgZ4VtdHNiaX6gS\|IwVSCjZoTldkAzPCCqcjDyJIF1KDJ7OECgcm0hMEmFOUCpMEBE\WyuIHP5Z4xmKD1iMD6wNlUh\|ryPLh?=	M4\2elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN\|E{Lz5zMkG5NFMyOzxxYU6=
A2780	MUDGeY5kfGmxbjDhd5NigQ>?	NYrLNWhpOzNyIH7N	M{DUcFI1KGi{	NXvtTYVPWGW{Y3XueIFo\SCDMke4NEBk\WyuczDpckBIOSCjZoTldkAzPCCqcjDyJIF1KDN\|MDDuUUApUUN3MDmsJGNmdGxiY4njcIUhRSByLkC2JO69VS5?	M{LsO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN\|E{Lz5zMkG5NFMyOzxxYU6=
A2780	NYHrTWc5TnWwY4Tpc44h[XO\|YYm=	NFXFco0zQThyIH7N	MkjENlQhcHJ?	NGPUdpVR\XKlZX70ZYdmKEF{N{iwJINmdGy\|IHnuJGcyKGGodHXyJFI1KGi{IIKgZZQhOjl6MDDuUUApUUN7MDmsJGNmdGxiY4njcIUhRSByLkC2NUDPxE1w	MnrUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN\|E{RC:jPh?=
A2780	Mk\qSpVv[3Srb36gZZN{[Xl?		NGfMOXYzPCCqcoO=	M3LrfWlvcGmkaYTpc44hd2ZiY3TrMY1m\GmjdHXkJHJjKHCqb4PwbI9zgWyjdHnvckBifCC\|ZYK4NFcwQDFzIHnuJIh2dWGwIFGyO\|gxKGOnbHzzJIFnfGW{IEK0JIhzew>?	M1vrXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NE[5PFA6Lz5zOES2PVgxQTxxYU6=
A2780	M2nlTmZ2dmO2aX;uJIF{e2G7		MXmyOEBpenN?	M1rjR2lvcGmkaYTpc44hd2ZiY3TrPU1u\WSrYYTl[EBTVkFicH;sNkBEXERicHjvd5Bpd3K7bHH0bY9vKGG2IIPldlIhcW5iaIXtZY4hSTJ5OECgZ4VtdHNiYX\0[ZIhOjRiaILz	NVHzPItGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0Olk5ODlpPkG4OFY6QDB7PD;hQi=>
A2780	M2rqfmZ2dmO2aX;uJIF{e2G7		Mk\FNlQhcHK\|	MnTRTY5pcWKrdHnvckBw\iClZHu3MY1m\GmjdHXkJHJPSSCyb3yyJGNVTCCyaH;zdIhwenmuYYTpc44h[XRic3XyOUBqdiCqdX3hckBCOjd6MDDj[YxteyCjZoTldkAzPCCqcoO=	MmjXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2Nkm4NFkoRjF6NE[5PFA6RC:jPh?=
A2780	M4LSXmFxd3C2b4Ppd{Bie3OjeR?=		M1u4XVI1KGi{cx?=	MU\JcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEF{N{iwJINmdGy\|IHHzd4V{e2WmIHHzJIFxeGWjcnHuZ4Uhd2ZiTXPsNUBxem:2ZXnuJIxmfmWuIHHmeIVzKDJ2IHjydy=>	MnvaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2Nkm4NFkoRjF6NE[5PFA6RC:jPh?=
DR-U2OS-GFP	M4faRmZ2dmO2aX;uJIF{e2G7	NYrLfFJ5OC5zIIXN	NGKzbIk2PiCqcoO=	MlyxVoVlfWO2aX;uJI9nKGixbX;sc4dwfXNicnXjc41jcW6jdHnvckBqdiCqdX3hckBFWi2XMl;TMWdHWCClZXzsd{BmgHC{ZYPzbY5oKElvU3PlTUBvfWOuZXHz[UBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gVmFFPTFibHX2[Ywh[XRiMD6xJJVOKGGodHXyJFU3KGi{czDifUBqdW23bn;icI91fGmwZx?=	MljjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2MUe0NVcoRjJzNEG3OFE4RC:jPh?=
A2780	M4DTNWZ2dmO2aX;uJIF{e2G7		NVf2XVdIOjRiaILz	MlvDTY5pcWKrdHnvckBw\iCFRFu5JIlvKGi3bXHuJGEzPzhyIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDv[kBTVkGSSVmgR3RFKHCqb4PwbI9zgWyjdHnvckBifCCVZYKyJIF1KEeLNUCgZ49v[2WwdILheIlwdiCjZoTldkAzPCCqcoOgZpkhX2W\|dHXyckBjdG:2dHnu[{BidmGueYPpdy=>	NUfLbIpMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFE4PjdpPkKzN\|AyPzZ5PD;hQi=>
A2780	NXnyfZY6S2WubDDjfYNt\SCjc4PhfS=>		NF\HTmozPCCqcoO=	NXWyWHBMS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hSTJ5OECgZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IFeyM20heGijc3WgZZQhdGW\|czD0bIFvKEeLNUCgZYZ1\XJiMkSgbJJ{KGK7IH\sc5ch[3m2b33leJJq[yCjbnHsfZNqew>?	M1q5[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CxO\|Y4Lz5{M{OwNVc3PzxxYU6=
A2780	MUXGeY5kfGmxbjDhd5NigQ>?		NUjMTpRUOjRiaILz	MoG1TY5pcWKrdHnvckBw\iCFRFu5JIlvKGi3bXHuJGEzPzhyIHPlcIx{KGG\|c3Xzd4VlKGG\|IHTve45z\We3bHH0bY9vKG:oIF3DUFEh[XRiR1m1NEB1dyB3WFfJOVAh[2:wY3XueJJifGmxbjDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0eIlv\yCjbnHsfZNqew>?	M17Xe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CxO\|Y4Lz5{M{OwNVc3PzxxYU6=
A2780	M4O1cGFxd3C2b4Ppd{Bie3OjeR?=		MYCyOEBpenN?	NHq4T4JKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFGyO\|gxKGOnbHzzJIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjDQRXJRKGOuZXH2ZYdmKGG2IFfJOVAhfG9iNWjHTVUxKGOxbnPlcpRz[XSrb36gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveJRqdmdiYX7hcJl{cXN?	M4TDT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CxO\|Y4Lz5{M{OwNVc3PzxxYU6=
A2780	MmHrSpVv[3Srb36gZZN{[Xl?		MXeyOEBpenN?	NWnFNpBTUW6qaXLpeIlwdiCxZjDDSGs6KGmwIHj1cYFvKEF{N{iwJINmdGy\|IHHzd4V{e2WmIHHzJIRwf26{ZXf1cIF1cW:wIH;mJGhFVTJiYYSgS2k2OCC2bzC1XGdKPTBiY3;uZ4VvfHKjdHnvckBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91fGmwZzDhcoFtgXOrcx?=	NYHvb4dSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFE4PjdpPkKzN\|AyPzZ5PD;hQi=>
MT4	MlnQRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			MUfBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhVkxiND2zJIlv\mWldHXkJIlvKE2WNDDj[YxteyCvZXHzeZJm\CCxbjDkZZkhPCCyb4P0JIlv\mWldHnvckBjgSCyMkSgZZN{[XluIFXDOVAhRSByLkCxOUDPxE1w	MkjRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUS4NFQoRjJ3OUG0PFA1RC:jPh?=
MT4	NEj1UJpEgXSxdH;4bYNqfHliYYPzZZk>			NXu2PHdoS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVVR2IHPlcIx{NCCLQ{WwJF0hOC5yNkeg{txONg>?	Ml[5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUS4NFQoRjJ3OUG0PFA1RC:jPh?=
Sf9	NID0eWhHfW6ldHnvckBie3OjeR?=		MoHtNVUhdWmwcx?=	NUDqU2FTUW6qaXLpeIlwdiCxZjDDSGszN2O7Y3zpckBGOSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDT[lkhcW6\|ZXP0JINmdGy\|IIXzbY5oKFWuaXfoeGNHTkuQSW\UVHJVWFCSU2HHT{1idWmmZTDzeYJ{fHKjdHWgZYZ1\XJiMUWgcYlveyCkeTDheZRwemGmaX;ndoFxcHluIFnDOVAhRSByLkGzJO69VS5?	M{DONFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUG0PFA1Lz5{NUmxOFgxPDxxYU6=
A549	MX\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NVPKR4dTOyCmYYnz	M{HqcWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB\|IHThfZMh[nliU2LCJI1mfGixZDygS2k2OCB;IECuNVQh\|ryPLh?=	M1;3SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUG0PFA1Lz5{NUmxOFgxPDxxYU6=
DU145	NUnXR4h4SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NYjRTFlTOyCmYYnz	M2fLXGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRGWxOFUh[2WubIOgZYZ1\XJiMzDkZZl{KGK7IGPSRkBu\XSqb3SsJGdKPTBiPTCwMlE2KM7:TT6=	MkH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUS4NFQoRjJ3OUG0PFA1RC:jPh?=
KB	NUDQV3E3SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NHKwbmU{KGSjeYO=	M1LDfWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1KgZ4VtdHNiYX\0[ZIhOyCmYYnzJIJ6KFOUQjDt[ZRpd2RuIFfJOVAhRSByLkG2JO69VS5?	NVvqW3BZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5NVQ5ODRpPkK1PVE1QDB2PD;hQi=>
KBVIN	NUjEPXliSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MWWzJIRigXN?	MnjoRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCNQm\JUkBk\WyuczDh[pRmeiB\|IHThfZMh[nliU2LCJI1mfGixZDygS2k2OCB;IECuNVgh\|ryPLh?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzNEiwOEc,OjV7MUS4NFQ9N2F-
HCT116	MULBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		Mn:0O\|IhcHK\|	M2\uXWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtfGm2ZYKtS4xwKHKnYXflcpQh[mG\|ZXSgZZN{[XliaX6gdJJme2WwY3Wgc4YhOTBnIH\leIFtKGKxdnnu[UB{\XK3bTygSWM2OCB;IECuNFM1KM7:TT6=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl6NUOwOUc,OjZ7OEWzNFU9N2F-
HCT116	MVPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MkfYO\|IhcHK\|	M{\IVGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtfGm2ZYKtS4xwKHKnYXflcpQh[mG\|ZXSgZZN{[XliaX6gdJJme2WwY3Wgc4YhOC54MkWlJIZmfGGuIHLveolv\SC\|ZYL1cUwhTUN3MDC9JFAvODV7IN88UU4>	NYnWfFFuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5PFU{ODVpPkK2PVg2OzB3PD;hQi=>
Sf9	NGnZNmVHfW6ldHnvckBie3OjeR?=		NHHYSmgyOCCvaX7z	MVXJcohq[mm2aX;uJI9nKGi3bXHuJGhqezZvdHHn[4VlKEOGS{mvZ5lkdGmwIGSxJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDz[lkh[2WubIOgeZNqdmdiR2PUMWNVTCCjczDzeYJ{fHKjdHWgZYZ1\XJiMUCgcYlveyCrbjDwdoV{\W6lZTDv[kBc\2GvbXGtN\|JRZUGWUDDifUBUTFNvUFHHSUBidmGueYPpd{whUUN3MDC9JFAvODB{NTFOwG0v	Ml7KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzN{GwN\|YoRjJ5MUexNFM3RC:jPh?=
Sf21	MVvGeY5kfGmxbjDhd5NigQ>?			MUHJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKG[3bHygcIVv\3SqIFOteIVzdWmwYXygTIl{Pi22YXfn[YQhS0SNOT;jfYNtcW5iVEGg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIGPmNlEhcW6\|ZXP0JINmdGy\|IIXzbY5oKFCGS4Tp[IUh[XNic4Xid5Rz[XSnLDDJR\|UxKD1iMD6wNVEh\|ryPLh?=	MoTPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzN{GwN\|YoRjJ5MUexNFM3RC:jPh?=
HeLa	NUnnUVBmS3m2b4TvfIlkcXS7IHHzd4F6		MYC3NkBpenN?	MVLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEOFNUCgQUAxNjF{IN88UU4>	NUG4b3hHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexO\|ExOzZpPkK3NVcyODN4PD;hQi=>
sf21	NVLXOodzTnWwY4Tpc44h[XO\|YYm=			NEWyT5ZKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJIh2dWGwIF6teIVzdWmwYXygTIl{Pi22YXfn[YQhS0SNNj;OMZRmem2rbnHsJGdUXC22YXfn[YQh[3mlbHnuJGQ{KGW6cILld5Nm\CCrbjDz[lIyKGOnbHzzJJV{cW6pIHjpd5RwdmViSEGgd5Vje3S{YYTlMEBKSzVyIE2gNE4{QTVizszNMi=>	NWn5bVl[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexO\|ExOzZpPkK3NVcyODN4PD;hQi=>
Sf21	MWHGeY5kfGmxbjDhd5NigQ>?			MmHKTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsJIxmdme2aDDDMZRmem2rbnHsJGhqezZvdHHn[4VlKEOGS{evZ5lkdGmwIFivUk11\XKvaX7hcEBIW1RvdHHn[4VlKE2DVEGg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIGPmNlEhcW6\|ZXP0JINmdGy\|IIXzbY5oKGOma{egd5Vje3S{YYTlJJBmeHSrZHWsJGlEPTBiPTCwMlUyPCEQvF2u	M{\mU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUexNFM3Lz5{N{G3NVA{PjxxYU6=
HepG2	MWrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MmK3O\|IhcHK\|	NWLwUFF2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtXGm2ZYKtS4xwKGG\|c3H5MEBGSzVyIE2gNE4yPDZ2IN88UU4>	M1TMT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEC3PVc2Lz5{OUSwO\|k4PTxxYU6=
KOPN8	NELZU\|ZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NIHSWY44OiCqcoO=	M1TuSWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1;QUlgh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcHRqfGW{LVfsc{Bie3OjeTygSWM2OCB;IECuNVkzPiEQvF2u	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTRyN{m3OUc,Ojl2MEe5O\|U9N2F-
SEM	NYW2bYNLSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Mni2O\|IhcHK\|	MkXvRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVRV2gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbGTpeIVzNUeubzDhd5NigSxiRVO1NEA:KDBwMkC0N{DPxE1w	MnXMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2MEe5O\|UoRjJ7NEC3PVc2RC:jPh?=
UOCB1	NHThN2lCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NILlfHc4OiCqcoO=	Mmr1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCXT1PCNUBk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XsWIl1\XJvR3zvJIF{e2G7LDDFR\|UxKD1iMD6yNFg1KM7:TT6=	NFi3S5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSwO\|k4PSd-Mkm0NFc6PzV:L3G+
KOPN8	M4fpOmFxd3C2b4Ppd{Bie3OjeR?=	M2DXbFAvPSC3TR?=	MUizJJRwKDJ2IHjydy=>	NEjWd5FKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFvPVG45KGOnbHzzJIF{e2W\|c3XkJIF{KHWycnXneYxifGmxbjDv[kBkdGWjdnXkJHBCWlBibHX2[Ywh[XRiMD61JJVOKGGodHXyJFMhfG9iMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTRyN{m3OUc,Ojl2MEe5O\|U9N2F-
KOPN8	MWLBdI9xfG:\|aYOgZZN{[Xl?	NYO2OWRWOC53IIXN	M3XJblEhcHJ?	MlrBTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCNT2DOPEBk\WyuczDhd5Nme3OnZDDhd{B2eHKnZ4XsZZRqd25ib3[gZ4xm[X[nZDDQRXJRKGyndnXsJIF1KDBwNTD1UUBxemVvdILlZZRm\CC5aYToJG5CSyCob4KgNUBpeiCjbnSgcYVie3W{ZXSgZYZ1\XJiMzD0c{AzPCCqcoOgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|	NXXsbXBpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0NFc6PzVpPkK5OFA4QTd3PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Cleaved caspase-8 / Cleaved caspase-9 / Cleaved caspase-3; PubMed: 31193061 Heliyon (C) Caspase activation was determined by western blotting. Flavopiridol treatment (300 nM) induced the expressions of cleaved caspase-8, -9 and -3 in a time-dependent manner. p-RNAPII / p-eIF4E / Mnk1 ; PubMed: 24572052 Reprod Sci After 24 h drug exposure, CDKI-73 or flavopiridol also abolished p-eIF4ES209 at 0.25 μM, indicating cellular inhibition of Mnk kinase activity. The same treatment with CDKI-73 or flavopiridol caused a loss in Mnk1 protein expression. CGP57380-treated cells abrogated p-RNAPIIS2 as well as p-eIF4E(S209) with a minimal effect on Mnk1 protein level. p-ERK / ERK / p-p38 / p-4EBP1 / 4EBP1 / p-S6 ; PubMed: 24572052 Reprod Sci 0.25 μM CDKI-73 or flavopiridol caused little changes in the phosphorylation of Erk and p38 MAPK; however, inhibited the 4E-BP1 phosphorylation (p-4E-BP1Thr70) by 24 h. CGP57380 had a minimal effect on these proteins. CDK2 / CDK4 / Cyclin A / p21 / p27 / Rb; PubMed: 24572052 Reprod Sci Effect of flavopiridol on cell cycle-related protein expression in uterine leiomyoma cells. Twenty-four hours after treatment, cell extracts were prepared and subjected to immunoblotting analysis. β-Actin was used as an internal loading control.	31193061 24572052
Growth inhibition assay	Cell viability; PubMed: 31193061 Heliyon The antiproliferative effect of flavopiridol on CCA cell lines was determined using an MTT assay. KKU-055, KKU-100, KKU-213 and KKU-214 cells were treated with 50, 100, 200 or 300 nM of flavopiridol at 24, 48 or 72 h. The percentage of cell number in vehicle control was taken as 100%. Data are mean ± SD of three independent experiments. *P < 0.05 in all CCA cell lines, significantly different for each time point compared with vehicle control.	31193061

体内研究

Flavopiridol按7.5 mg/kg剂量处理P388 小鼠白血病，持续7天，具有轻微抗癌活性，导致%T/C值为110,且有效作用于皮下抑制人A2780卵巢癌的裸鼠，细胞对数杀灭(LCK)为1.5 。^[5] Flavopiridol按 1-2.5 mg/kg 剂量处理小鼠，持续10天，通过抑制滑膜增生和关节损伤，而显著抑制胶原性关节炎，这种作用存在剂量依赖性，然而抗II型胶原(CII) 抗体的血清浓度，和II型胶原对应的增殖维持不变。^[6]

激酶实验： ^{[1] [2] [3]}	- 合并 CDK 激酶实验: CDK1/cyclin B1 激酶实验中, 激酶反应包含100 ng表达 GST-CDK1/cyclin B1(人)复合体的杆状病毒, 1 μg 组蛋白 HI, 0.2 μCi [γ-³³P]ATP, 25 μM ATP溶于 50 μL 激酶buffer (50 mM Tris, pH 8.0, 10 mM MgCl₂, 1 mM EGTA, 0.5 mM DTT)。CDK2/cyclin E 激酶实验中, 激酶反应包含5 ng表达 GST-CDK2/cyclin E (人)复合体的杆状病毒, 0.5 μg GST-RB 融合蛋白(成视网膜细胞瘤蛋白776-928 氨基酸), 0.2 μCi [γ-³³P]ATP, 25 μM ATP溶于 50 μL 激酶buffer (50 mM Hepes, pH 8.0, 10 mM MgCl₂, 1 mM EGTA, 2 mM DTT)。CDK4/cyclin D1激酶实验中, 激酶反应含150 ng 表达GST-CDK4/cyclin D1 (人)的杆状病毒, 280 ng Stag-cyclin D1, 0.5 μg GST-RB 融合蛋白(成视网膜细胞瘤蛋白776-928 氨基酸), 0.2 μCi [γ-³³P]ATP, 25 μM ATP 溶于50 μL激酶 buffer (50 mM Hepes, pH 8.0, 10 mM MgCl₂, 1 mM EGTA, 2 mM DTT)。30^oC下， CDK1 和CDK2反应温育45分钟， CDK4反应温育1小时，加入终浓度为15%的冰冻三氯乙酸(TCA) 终止反应。使用Filtermate通用收集器，收集TCA沉淀物转移到GF/C 非过滤板上，使用TopCount 96孔液体闪烁计数器测量过滤数。Flavopiridol溶于 10 mM二甲基甲酰胺(DMF) 中，测定六种浓度，每种重复测三次。实验中 DMF终浓度为 2%。通过回归曲线分析获得IC50值，变异系数为 16%。测定Flavopiridol作用于 CDK6的活性, 进行过滤-结合实验。反应混合物按如下结合： 2 μL CDK6 (0.7 mg/μL), 5 μL 组蛋白 H1 (6 mg/mL), 14 μL 激酶 buffer (60 mM β-甘油磷酸, 30 mM p-磷酸硝基苯酯, 25 mM MOPS (pH 7.0), 5 mM EGTA, 15 mM MgCl₂, 1 mM DTT, 0.1 mM 钒酸钠), 在50% DMSO中稀释的 3 μL 浓度不断增长的Flavopiridol ，及6 μL ³³P-ATP (1 mCi/mL)，非放射性 ATP，浓度为90 μM，(终浓度为15 μM)。加入³³P-ATP开始反应。反应在30^oC下温育20分钟。25 μL等分的上清液点样到 Whatman P81 磷酸纤维素膜上。使用1% 磷酸溶液冲洗过滤器5次。在1 mL闪烁液存在时测定湿过滤器。使用 50 nM 重组Cdk9/cyclin T在 50 mM HEPES pH 7.5, 10 mM MgCl₂, 1 mM DTT, 3 μM Na₃VO₄, 150 μM RNA 聚合酶CDT 肽和80 μM ATP中测定Cdk9活性。在相同buffer中使用37 nM纯化激酶，在200 μM ATP 存在时，10 μM 髓鞘蛋白（MBP）作为底物，进行Cdk7检测实验。使用强阴离子交换剂-为基础的检测实验或闪烁接近实验测定Flavopiridol 作用于CDK9和CDK7的效果。通过剂量反应曲线计算IC50值。
细胞实验： ^[5]	- 合并 Cell lines: MCF-7, LNCAP, PC3, HCT116, CACO-2, A549, HL60, K562, 等等 Concentrations: 溶于DMSO,终浓度为 ~10 μM Incubation Time: 72小时 Method: 使用不同浓度 Flavopiridol 处理细胞72小时，加入四唑染料，MTS和吩嗪硫酸甲酯。3 小时后,在492 nm处测定吸光值,与存活细胞数成比例。结果表示为IC50值。为了分析细胞周期，细胞在仲甲醛和乙醇中混合，冲洗，然后再悬浮在TdT 酶和 FITC-dUTP染色液中,再冲洗，使用PI染色，随后进行RNA酶处理，最后使用流式细胞仪分析。 (Only for Reference)
动物实验： ^[5]	- 合并 Animal Models: 腹腔注射P388 腹水白血病细胞的雌性Balb/c×DBA/2J F1小鼠,皮下移植A2780, Br-cycE, 或A431细胞的Balb/c nu/nu裸鼠 Dosages: ~7.5 mg/kg/day Administration: 腹腔注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	15 mg/mL (37.32 mM)
	Water	Insoluble
	Ethanol	''''8 mg/mL
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+30% PEG 300+ddH2O	2.5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Flavopiridol (L86-8275) SDF

分子量	401.84
化学式	C₂₁H₂₀ClNO₅
CAS号	146426-40-6
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	NSC 649890 HCl, HMR-1275, Alvocidib

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03441555	Completed	Drug: Venetoclax\|Drug: Alvocidib	Acute Myeloid Leukemia (AML)	AbbVie\|Sumitomo Dainippon Pharma Oncology Inc	May 30 2018	Phase 1
NCT03298984	Completed	Drug: Alvocidib\|Drug: Cytarabine\|Drug: Daunorubicin	Acute Myeloid Leukemia	Sumitomo Dainippon Pharma Oncology Inc	September 25 2017	Phase 1
NCT00112723	Terminated	Drug: alvocidib	Adult Lymphocyte Depletion Hodgkin Lymphoma\|Adult Lymphocyte Predominant Hodgkin Lymphoma\|Adult Mixed Cellularity Hodgkin Lymphoma\|Adult Nodular Sclerosis Hodgkin Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult T-cell Leukemia/Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides/Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Multiple Myeloma\|Splenic Marginal Zone Lymphoma\|Stage I Multiple Myeloma\|Stage II Multiple Myeloma\|Stage III Multiple Myeloma\|Waldenström Macroglobulinemia	National Cancer Institute (NCI)	December 2005	Phase 1\|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

研究领域

产品类型

定制您的化合物库

Flavopiridol (L86-8275)

客户使用Selleck生产的Flavopiridol (L86-8275)发表文献81篇：

产品安全说明书

CDK抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Flavopiridol (L86-8275) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

技术支持

CDK Signaling Pathway Map

相关CDK产品